These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37139287)

  • 1. A Descriptive Study on Opioid Misuse Prevalence and Office-Based Buprenorphine Access in Ohio Prior to the Removal of the Drug Addiction Treatment Act of 2000 Waiver.
    McKnight ER; Dong Q; Brook DL; Hepler SA; Kline DM; Bonny AE
    Cureus; 2023 Mar; 15(3):e36903. PubMed ID: 37139287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Relationship Between Hepatitis C Virus Rates and Office-Based Buprenorphine Access in Ohio.
    Brook DL; Hetrick AT; Chettri SR; Schalkoff CA; Sibley AL; Lancaster KE; Go VF; Miller WC; Kline DM
    Open Forum Infect Dis; 2021 Jun; 8(6):ofab242. PubMed ID: 34159217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
    Andrilla CHA; Moore TE; Patterson DG; Larson EH
    J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.
    Ghertner R
    Drug Alcohol Depend; 2019 Nov; 204():107527. PubMed ID: 31525570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018.
    Conway KP; Khoury D; Hilscher R; Aldridge AP; Parker SJ; Zarkin GA
    Addict Sci Clin Pract; 2022 Jan; 17(1):5. PubMed ID: 35101112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder.
    Andrilla CHA; Patterson DG
    J Rural Health; 2022 Jan; 38(1):87-92. PubMed ID: 33733547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial.
    Stopka TJ; Babineau DC; Gibson EB; Knott CE; Cheng DM; Villani J; Wai JM; Blevins D; David JL; Goddard-Eckrich DA; Lofwall MR; Massatti R; DeFiore-Hyrmer J; Lyons MS; Fanucchi LC; Harris DR; Talbert J; Hammerslag L; Oller D; Balise RR; Feaster DJ; Soares W; Zarkin GA; Glasgow L; Oga E; McCarthy J; D'Costa L; Chahine R; Gomori S; Dalvi N; Shrestha S; Garner C; Shadwick A; Salsberry P; Konstan MW; Freisthler B; Winhusen J; El-Bassel N; Samet JH; Walsh SL
    JAMA Netw Open; 2024 Feb; 7(2):e240132. PubMed ID: 38386322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Geographic Distribution of Obstetrician-Gynecologists Who Treat Medicaid Enrollees and Are Trained to Prescribe Buprenorphine.
    Nguemeni Tiako MJ; Culhane J; South E; Srinivas SK; Meisel ZF
    JAMA Netw Open; 2020 Dec; 3(12):e2029043. PubMed ID: 33306115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial access to buprenorphine-waivered prescribers in the HEALing communities study: Enhanced 2-step floating catchment area analyses in Massachusetts, Ohio, and Kentucky.
    Shrestha S; Lindstrom MR; Harris D; Rock P; Srinivasan S; Pustz JC; Bayly R; Stopka TJ
    J Subst Use Addict Treat; 2023 Jul; 150():209077. PubMed ID: 37211155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver.
    Lanham HJ; Papac J; Olmos DI; Heydemann EL; Simonetti N; Schmidt S; Potter JS
    JAMA Netw Open; 2022 May; 5(5):e2212419. PubMed ID: 35552721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between buprenorphine provider availability and opioid deaths among US counties.
    Jones CW; Christman Z; Smith CM; Safferman MR; Salzman M; Baston K; Haroz R
    J Subst Abuse Treat; 2018 Oct; 93():19-25. PubMed ID: 30126537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program.
    Rowe CL; Ahern J; Hubbard A; Coffin PO
    J Subst Abuse Treat; 2022 Jan; 132():108452. PubMed ID: 34098203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine.
    Andrilla CHA; Jones KC; Patterson DG
    J Rural Health; 2020 Mar; 36(2):187-195. PubMed ID: 31650634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
    Krawczyk N; Jent V; Hadland SE; Cerdá M
    J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing patterns of buprenorphine waivered physicians.
    Thomas CP; Doyle E; Kreiner PW; Jones CM; Dubenitz J; Horan A; Stein BD
    Drug Alcohol Depend; 2017 Dec; 181():213-218. PubMed ID: 29096292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment Organizations.
    Molfenter T; Sherbeck C; Zehner M; Starr S
    J Addict Behav Ther Rehabil; 2015; 4(2):. PubMed ID: 26380328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.
    Gregory HM; Hill VM; Parker RW
    Cureus; 2021 Nov; 13(11):e19870. PubMed ID: 34976492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.